We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Temozolomide Chronotherapy for High Grade Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02781792
Recruitment Status : Active, not recruiting
First Posted : May 24, 2016
Last Update Posted : October 10, 2022
Sponsor:
Information provided by (Responsible Party):
Washington University School of Medicine

Tracking Information
First Submitted Date  ICMJE May 20, 2016
First Posted Date  ICMJE May 24, 2016
Last Update Posted Date October 10, 2022
Actual Study Start Date  ICMJE August 11, 2016
Estimated Primary Completion Date July 14, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 5, 2022)
  • Feasibility of patient treatment compliance as measured by at least 80% compliance with assigned administration time [ Time Frame: Completion of treatment (estimated to be 6 months) ]
    Compliance is defined as no more than one of five doses of temozolomide per cycle taken outside of the assigned administration time.
  • Duration of response [ Time Frame: Through completion of follow-up (estimated to be 30 months) ]
    • Response and progression will be evaluated in this study using the updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology (RANO) working group guideline [JCO 28(11): 1963-1972, 2010].
    • The duration of overall response is measured from the time measurement criteria are met for complete response (CR) or partial response (PR) (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).
Original Primary Outcome Measures  ICMJE
 (submitted: May 20, 2016)
  • Feasibility of patient treatment compliance as measured by at least 80% compliance with assigned administration time [ Time Frame: Completion of treatment (estimated to be 6 months) ]
    Compliance is defined as no more than one of five doses of temozolomide per cycle taken outside of the assigned administration time.
  • Duration of response [ Time Frame: Until disease progression (estimated to be 6 months) ]
    • Response and progression will be evaluated in this study using the updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology (RANO) working group guideline [JCO 28(11): 1963-1972, 2010].
    • The duration of overall response is measured from the time measurement criteria are met for complete response (CR) or partial response (PR) (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 5, 2022)
  • Number of patients experiencing grade 3 or 4 lymphopenia, thrombocytopenia, neutropenia and anemia in each group as measured by standard blood draws [ Time Frame: Completion of treatment (estimated to be 6 months) ]
    • Lymphopenia grade 3 is <500-200/mm3 and grade 4 is <200/mm3
    • Leukopenia grade 3 is <2000-1000/mm3 and grade 4 is <1000/mm3
    • Neutropenia grade 3 is <1000-500/mm3 and grade 4 is <500/mm3
    • Thrombocytopenia grade 3 is <50,000-25,000/mm3 and grade 4 is <25,000/mm3
    • Anemia grade 3 is <8.0-6.5 g/dL and grade 4 is <6.5 g/dL
  • Quality of life as measured by FACT-Br score [ Time Frame: 1 month after completion of treatment (estimated to be 7 months) ]
  • Progression-free survival (PFS) [ Time Frame: Through completion of follow-up (estimated to be 30 months) ]
    PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.
  • Overall survival [ Time Frame: Through completion of follow-up (estimated to be 30 months) ]
  • Comparison of the level of sleep disruption in sleep-wake cycles of participants receiving temozolomide in the morning versus participants receiving temozolomide in the evening [ Time Frame: Through 1 month after completion of treatment (estimated to be 7 months) ]
    • The data will be collected through the ActTrust Condor Instrument Watch and the Sleep Questionniare.
    • The qualitative data (sleep questionnaire) will be used with quantitative data (collected via the ActTrust watch) to assess the level of sleep disruption in sleep/wake cycles
Original Secondary Outcome Measures  ICMJE
 (submitted: May 20, 2016)
  • Number of patients experiencing grade 3 or 4 lymphopenia, thrombocytopenia, neutropenia and anemia in each group as measured by standard blood draws [ Time Frame: Completion of treatment (estimated to be 6 months) ]
    • Lymphopenia grade 3 is <500-200/mm3 and grade 4 is <200/mm3
    • Leukopenia grade 3 is <2000-1000/mm3 and grade 4 is <1000/mm3
    • Neutropenia grade 3 is <1000-500/mm3 and grade 4 is <500/mm3
    • Thrombocytopenia grade 3 is <50,000-25,000/mm3 and grade 4 is <25,000/mm3
    • Anemia grade 3 is <8.0-6.5 g/dL and grade 4 is <6.5 g/dL
  • Quality of life as measured by FACT-Br score [ Time Frame: 2 months after completion of treatment (estimated to be 8 months) ]
  • Progression-free survival (PFS) [ Time Frame: Until disease progression (estimated to be 6 months) ]
    PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.
  • Overall survival [ Time Frame: Until patient death (estimated to be 15 months) ]
    -Patient will complete sleep journal every day while taking drug
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Temozolomide Chronotherapy for High Grade Glioma
Official Title  ICMJE A Randomized Feasibility Study Evaluating Temozolomide Chronotherapy for High Grade Glioma
Brief Summary

Temozolomide (TMZ) is the chemotherapy drug approved by the FDA to increase survival in glioblastoma (GBM) patients beyond surgical resection and radiation therapy alone. Give its activity in astrocytomas, TMZ is commonly used in grade III anaplastic astrocytoma (AA) as well. Both grade III AA and grade IV GBM are high grade gliomas (HGG). The short half-life of this drug and known oscillations in DNA damage repair make it an ideal candidate for chronotherapy.

Chronotherapy is the improvement of treatment outcomes by minimizing treatment toxicity and maximizing efficacy through delivery of a medication according to the timing of biological rhythms within a patient. Chronotherapy has improved outcomes through the reduction of side effects and increase in anti-tumor activity for a variety of cancers, but has never been applied to the treatment of gliomas.

Based on the preliminary preclinical data for chronotherapeutic TMZ treatment of intracranial glioma xenografts and the success of chronotherapy in the treatment of other cancers, the invesitgators hypothesize that the timing of TMZ treatment will alter its efficacy and toxicity.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Glioma
  • Glioblastoma Multiforme
Intervention  ICMJE
  • Drug: Temozolomide
    -Given standard of care
    Other Name: Temodar
  • Other: Functional Assessment of Cancer Therapy - Brain
    • 23-item questionnaire that can be completed in 5 to 10 minutes with little or no assistance in patients who are not neurologically incapacitated. This brain subscale is usually used along with the core (general) questionnaire [2] that includes 27 items.
    • Patients rate all 5 items using a five-point Likert scale ranging from 0 "not at all" to 4 "very much." Overall, higher ratings suggest higher QOL. Items are totaled to produce the following subscales, along with an overall QOL score: physical well-being (7 items); social/family well-being (7 items); emotional well-being (6 items); functional well-being (7 items); and concerns relevant to patients with brain tumors (23 items)
    • The sleep portion of this questionnaire consists of 17 questions about sleeping patterns and the ability to rate severity of insomnia.
    Other Name: FACT-Br
  • Other: ActTrust Condor Instrument Watch
    -Will be required to wear 24 hours per day and will only be removed at specified data collection time points
Study Arms  ICMJE
  • Experimental: Arm 1: Temozolomide morning
    • Temozolomide will be given as per standard of care. Typical dosing is 150 to 200 mg/m^2 on Days 1 through 5 of a 28-day treatment cycle. Patients will be randomized to take their temozolomide doses in the morning (before 10:00).
    • FACT-Br quality of life at baseline, at the beginning of each cycle of chemotherapy, and 1 month after the final chemotherapy treatment
    Interventions:
    • Drug: Temozolomide
    • Other: Functional Assessment of Cancer Therapy - Brain
    • Other: ActTrust Condor Instrument Watch
  • Experimental: Arm 2: Temozolomide evening
    • Temozolomide will be given as per standard of care. Typical dosing is 150 to 200 mg/m2 on Days 1 through 5 of a 28-day treatment cycle. Patients will be randomized to take their temozolomide doses in the evening (after 20:00).
    • FACT-Br quality of life at baseline, at the beginning of each cycle of chemotherapy, and 1 month after the final chemotherapy treatment
    Interventions:
    • Drug: Temozolomide
    • Other: Functional Assessment of Cancer Therapy - Brain
    • Other: ActTrust Condor Instrument Watch
Publications * Damato AR, Katumba RGN, Luo J, Atluri H, Talcott GR, Govindan A, Slat EA, Weilbaecher KN, Tao Y, Huang J, Butt OH, Ansstas G, Johanns TM, Chheda MG, Herzog ED, Rubin JB, Campian JL. A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma. Neurooncol Pract. 2022 Jan 31;9(3):193-200. doi: 10.1093/nop/npac003. eCollection 2022 May.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: July 16, 2021)
42
Original Estimated Enrollment  ICMJE
 (submitted: May 20, 2016)
20
Estimated Study Completion Date  ICMJE July 14, 2024
Estimated Primary Completion Date July 14, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Newly diagnosed and recurrent high grade gliomas (WHO grades III & IV) and high risk WHO grade II gliomas who are to begin treatment with monthly high dose temozolomide therapy.
  • Scheduled to receive adjuvant temozolomide therapy after having completed concurrent temozolomide and radiation therapy.
  • At least 18 years of age.
  • Karnofsky performance status ≥ 60%
  • Ability to understand and willingness to sign an IRB approved written informed consent document

Exclusion Criteria:.

-Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02781792
Other Study ID Numbers  ICMJE 201605081
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Washington University School of Medicine
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Washington University School of Medicine
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Milan Chheda, M.D. Washington University School of Medicine
PRS Account Washington University School of Medicine
Verification Date October 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP